Search Tag: oncology
2025 25 Oct
Prostate-specific membrane antigen (PSMA) PET/CT has transformed prostate cancer assessment and is now embedded in guideline-recommended care. Yet the usefulness of advanced imaging depends on how consistently results are communicated. An analysis of consecutive external PSMA PET/CT reports received at a single tertiary centre highlights substantial...Read more
2025 10 Sep
Lung cancer remains the leading cause of cancer mortality in women, claiming more lives each year than breast and ovarian cancers combined. Low-dose CT can reduce lung cancer deaths by at least 20 percent through detection at earlier, more treatable stages and evidence indicates that women may benefit even more than men from annual screening....Read more
2025 10 Sep
Lung cancer remains the leading cause of cancer mortality in women, claiming more lives each year than breast and ovarian cancers combined. Low-dose CT can reduce lung cancer deaths by at least 20 percent through detection at earlier, more treatable stages and evidence indicates that women may benefit even more than men from annual screening....Read more
2025 02 Sep
Accurate identification and quantification of lung cancer lesions is critical for diagnosis, staging, treatment planning and disease monitoring. While primary tumours receive most attention in radiological evaluations, patients often present with multiple lesions that must also be assessed for a complete picture of disease burden. Traditional...Read more
2025 25 Aug
Pancreatic ductal adenocarcinoma remains one of the deadliest malignancies, largely due to its frequent diagnosis at advanced stages. While contrast-enhanced computed tomography remains the standard imaging method for pancreatic cancer evaluation, nearly 40% of early-stage tumours can still go undetected. Deep learning approaches have emerged...Read more
2025 18 Aug
Affidea, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a strategic partnership with Skin Analytics, a pioneering AI company in dermatology care. This collaboration supports Affidea’s long-term vision of leveraging digital innovations to improve patient...Read more
2025 18 Aug
Affidea, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a strategic partnership with Skin Analytics, a pioneering AI company in dermatology care. This collaboration supports Affidea’s long-term vision of leveraging digital innovations to improve patient...Read more
2025 16 Aug
Radiomics and machine learning are increasingly explored as tools to improve prognostic accuracy in oncology. Baseline ^18F-FDG PET/CT scans are widely used in diffuse large B-cell lymphoma to inform treatment decisions and assess disease response. Alongside standard uptake values and total metabolic tumour volume, radiomic features offer additional...Read more
2025 22 Jul
Precision medicine promises personalised and right-sized care, moving beyond one-size-fits-all treatment plans. However, delivering on that promise remains challenging, particularly in oncology, where clinical guidelines evolve rapidly, and data silos hinder timely, patient-specific decisions. In breast cancer care, these challenges have contributed...Read more
2025 22 Jul
Precision medicine promises personalised and right-sized care, moving beyond one-size-fits-all treatment plans. However, delivering on that promise remains challenging, particularly in oncology, where clinical guidelines evolve rapidly, and data silos hinder timely, patient-specific decisions. In breast cancer care, these challenges have contributed...Read more
2025 12 Jul
Achieving clear resection margins is critical in the surgical management of locally recurrent rectal cancer (LRRC), as it is closely linked to improved overall and disease-free survival. However, the feasibility of complete resection varies widely depending on tumour location and biological behaviour. A recent retrospective study published in...Read more
2025 06 Jul
Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate of just 11%. While most cases are sporadic, a notable subset arises in individuals with hereditary or familial predispositions. These high-risk individuals (HRIs) face a significantly elevated lifetime risk of developing pancreatic cancer. Early detection...Read more
2024 09 Dec
Hypopharyngeal Squamous Cell Carcinoma (HSCC) is a particularly aggressive form of head and neck cancer, often characterised by late-stage diagnosis, high rates of recurrence and poor survival outcomes. One critical factor influencing the prognosis of HSCC is lymphovascular invasion (LVI), which occurs when cancer cells infiltrate lymphatic or...Read more
2024 30 Nov
Dynamic FDG PET/CT imaging has significantly advanced the diagnosis and management of gynaecological cancers by enhancing precision in distinguishing pathological from physiological uptake. Conventional static imaging often struggles with false positives, particularly in regions like the abdomen and pelvis, where physiological activity can mimic...Read more
2024 21 May
Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios Investing in disruptive innovation that will shape the future of medicine and drive long-term growth Decoupling carbon emissions from revenue growth AstraZeneca revealed its bold ambition to deliver...Read more
2024 21 May
Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios Investing in disruptive innovation that will shape the future of medicine and drive long-term growth Decoupling carbon emissions from revenue growth AstraZeneca revealed its bold ambition to deliver...Read more
2022 21 Apr
The Axiom REACH Foundation announced the appointment of its board of trustees, adding accomplished oncology and rare disease executives. The board will comprise of Robert LaCaze , Biren Amin , and Ambaw Bellete , and Hafiz Sikder , founder and Executive Director. Robert LaCaze will serve as co-director of the REACH board, bringing a wealth...Read more
2019 05 Nov
Genomic testing is being gradually adopted in healthcare assisting in defining treatments for selected disorders. . One of the primary fields for these tests are cancer mutations. Genomic tests on cancer cells may help to determine what types of treatment would be effective. Some insist that in cases of advanced cancer oncologists...Read more
2017 25 Apr
Mammography is the standard imaging examination for breast cancer screening. Interestingly, a new study published in JAMA Oncology provides no audit-based evidence on specific age cut-off point for breast cancer screening. The finding supports guidelines for encouraging screening on the basis of individual patient values, comorbidities, and health...Read more
2016 20 Dec
In 2014, more than 1.1 million emergency care cases in Abu Dhabi alone Projected demand for major trauma in Abu Dhabi is double that of major trauma rates in the UK and Australia Emirates Society of Emergency Medicine (ESEM) to collaborate with Arab Health Congress to support Emergency Medicine physicians in developing their skills and...Read more
2016 05 Oct
A new report from Sectra shows oncologists’ views on the service they receive from radiology and how they would rate different changes. Better communication stands out as key in taking cancer care to the next level. As the number and complexity of cancer cases increase, radiology spends more and more time providing service to oncologists. This...Read more